Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

11.43USD
4:00pm EDT
Change (% chg)

$0.17 (+1.51%)
Prev Close
$11.26
Open
$11.19
Day's High
$11.52
Day's Low
$11.12
Volume
123,868
Avg. Vol
218,857
52-wk High
$14.45
52-wk Low
$2.54

Chart for

About

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from... (more)

Overall

Beta: 1.71
Market Cap(Mil.): $594.74
Shares Outstanding(Mil.): 52.77
Dividend: --
Yield (%): --

Financials

  FATE.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -1.02 -- --
ROI: -49.34 -0.73 12.97
ROE: -57.14 -2.77 14.84

BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune

* FATE THERAPEUTICS ANNOUNCES ADDITIONAL CLINICAL DATA FROM PHASE 1 STAGE OF PROTECT CLINICAL TRIAL OF PROTMUNE™

Mar 19 2018

BRIEF-Fate Therapeutics Q4 Loss Per Share $0.29​

* FATE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

Mar 05 2018

Earnings vs. Estimates